BCDA

Business Context and Reporting Period

Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: BioCardia is a clinical-stage biotechnology company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Key programs include the CardiAMP autologous cell therapy for ischemic heart failure and chronic myocardial ischemia, the CardiALLO allogeneic mesenchymal stem cell therapy, and the PulmALLO program for acute respiratory distress syndrome. The company also develops delivery systems (Helix, Morph DNA) and imaging software (Heart3D).

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total costs and expenses decreased to $3.89 million for the six months ended June 30, 2026, from $4.78 million in the prior year period. Research and development (R&D) expenses declined to $2.13 million from $2.90 million, primarily due to the closeout of the CardiAMP Heart Failure Trial, partially offset by early enrollment in the CardiAMP Heart Failure II Trial and regulatory activities in Japan.
• Equity Financing: The company significantly increased equity fundraising activity. During the six months ended June 30, 2026, the company sold approximately 4.19 million shares under its At-The-Market (ATM) facility, generating gross proceeds of $5.31 million. This compares to $0.56 million in gross proceeds from the ATM facility in the same period in 2025.
• Liquidity Improvement: Cash and cash equivalents increased from $2.50 million as of December 31, 2025, to $4.12 million as of June 30, 2026, driven by financing activities.
• Share Count: Outstanding common shares increased from 10.76 million at December 31, 2025, to 14.98 million at June 30, 2026, due to ATM sales and warrant exercises.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern beyond January 2027. With approximately $4.1 million in cash, current resources are insufficient to fund planned expenditures and obligations beyond that date without additional capital.
• Funding Strategy: The company plans to raise additional capital through non-dilutive collaboration and licensing arrangements, debt, or equity financing. The ATM facility is currently exhausted ($0 remaining capacity).
• Clinical Progress:
  • CardiAMP (Heart Failure): Preparing data for submission to Japan's PMDA and the U.S. FDA. The FDA indicated the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA).
  • CardiAMP (Chronic Myocardial Ischemia): Phase III results presented in May 2026 showed positive outcomes, including increased exercise tolerance and reduced angina episodes.
  • CardiALLO: Phase 1/2 dose escalation completed with no adverse events; proceeding to randomized study.
• Risks: Risks include the inability to raise additional capital, potential delisting from Nasdaq if listing requirements are not met, and the uncertainty of clinical trial outcomes and regulatory approvals.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing agreements post-June 30, 2026.
• ATM Capacity: Confirm if the company has filed a new registration statement to replenish the exhausted At-The-Market facility.
• Regulatory Submissions: Monitor the status of the regulatory submission to Japan's PMDA and the FDA PMA pathway for the CardiAMP system.
• Nasdaq Compliance: Review current stock price and market cap to ensure continued compliance with Nasdaq listing requirements.
• Debt Obligations: Confirm there are no undisclosed debt covenants or senior securities that could be triggered by liquidity constraints.